- Home
- AYTU vs KZIA Comparison
AYTU vs KZIA Comparison
Compare AYTU & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- KZIA
- Stock Information
- Founded
- AYTU N/A
- KZIA 1994
- Country
- AYTU United States
- KZIA Australia
- Employees
- AYTU N/A
- KZIA N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- KZIA Health Care
- Exchange
- AYTU Nasdaq
- KZIA Nasdaq
- Market Cap
- AYTU 23.0M
- KZIA 9.0M
- IPO Year
- AYTU N/A
- KZIA 1999
- Fundamental
- Price
- AYTU $2.36
- KZIA $7.03
- Analyst Decision
- AYTU Strong Buy
- KZIA Strong Buy
- Analyst Count
- AYTU 3
- KZIA 3
- Target Price
- AYTU $9.17
- KZIA $16.00
- AVG Volume (30 Days)
- AYTU 315.3K
- KZIA 188.3K
- Earning Date
- AYTU 11-12-2025
- KZIA 11-14-2025
- Dividend Yield
- AYTU N/A
- KZIA N/A
- EPS Growth
- AYTU N/A
- KZIA N/A
- EPS
- AYTU N/A
- KZIA N/A
- Revenue
- AYTU $66,382,000.00
- KZIA $1,549,158.00
- Revenue This Year
- AYTU N/A
- KZIA N/A
- Revenue Next Year
- AYTU $19.03
- KZIA $49.25
- P/E Ratio
- AYTU N/A
- KZIA N/A
- Revenue Growth
- AYTU 1.84
- KZIA 248983.08
- 52 Week Low
- AYTU $0.95
- KZIA $2.86
- 52 Week High
- AYTU $2.82
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- AYTU 55.65
- KZIA 49.80
- Support Level
- AYTU $2.23
- KZIA $6.82
- Resistance Level
- AYTU $2.42
- KZIA $7.29
- Average True Range (ATR)
- AYTU 0.15
- KZIA 0.46
- MACD
- AYTU 0.02
- KZIA 0.06
- Stochastic Oscillator
- AYTU 70.96
- KZIA 59.21
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.